Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADAPTIN BIO, INC.NONE · Entity 9083 | Director | September 08, 2025 | September 10, 2025 |
| NEOGENOMICS INCNEO · Entity 2096 | Director · Chief Executive Officer | April 01, 2026 | April 03, 2026 |
| Streamex Corp.BSGM · Entity 1816 | Director | December 28, 2021 | April 25, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADAPTIN BIO, INC.
Report date September 08, 2025 · Filed September 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2035-09-07 | Direct | 109,847 |
Reported balance
After 2025-09-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-08 · Grant · Acquired 109,847 · Balance 109,847 F1: The stock option vests in equal monthly installments on the last day of each calendar month over 48 months beginning on September 8, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in equal monthly installments on the last day of each calendar month over 48 months beginning on September 8, 2025.
NEOGENOMICS INC
Report date April 01, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 133,111 |
Ending reported balance
After 2026-04-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-01 · Exercise / conversion · Acquired 140,498 · Balance 178,564 Row 2 · 2026-04-01 · Tax withholding · Disposed 45,453 · Balance 133,111 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 280,998 |
Reported balance
After 2026-04-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-01 · Exercise / conversion · Disposed 140,498 · Balance 280,998 F1: On April 1, 2025, Mr. Zook was granted 421,496 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F2: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 406,918 |
Reported balance
Holding disclosure · report date 2026-04-01 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 406,918 F7: On March 1, 2026, Mr. Zook was granted 406,918 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F2: Once vested, the shares of common stock are not subject to expiration. |
| Common StockSEC Table I · non-derivative | IndirectAmended and Restated Anthony P. Zook Living Trust | 18,900 |
Reported balance
Holding disclosure · report date 2026-04-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 18,900 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.82 · Expires 2033-08-10 | Direct | 8,353 |
Reported balance
Holding disclosure · report date 2026-04-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 8,353 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2034-06-01 | Direct | 8,672 |
Reported balance
Holding disclosure · report date 2026-04-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 8,672 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.44 · Expires 2035-04-01 | Direct | 729,927 |
Reported balance
Holding disclosure · report date 2026-04-01 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 729,927 F3: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%. F4: On April 1, 2025, Mr. Zook was granted 729,927 stock options. The options vest ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.81 · Expires 2036-03-01 | Direct | 675,676 |
Reported balance
Holding disclosure · report date 2026-04-01 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 675,676 F5: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 and multiplied by 110%. F6: On March 1, 2026, Mr. Zook was granted 675,676 stock options. The options vest ratably over the first three anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 1, 2025, Mr. Zook was granted 421,496 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
F2: Once vested, the shares of common stock are not subject to expiration.
F3: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%.
F4: On April 1, 2025, Mr. Zook was granted 729,927 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F5: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 and multiplied by 110%.
F6: On March 1, 2026, Mr. Zook was granted 675,676 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F7: On March 1, 2026, Mr. Zook was granted 406,918 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
Streamex Corp.
Report date December 28, 2021 · Filed April 25, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 · Expires 2031-12-28 | Direct | 50,000 |
Reported balance
After 2021-12-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-12-28 · Grant · Acquired 50,000 · Balance 50,000 F1: The stock options shall be fully vested and exercisable as of December 28, 2021, the date of the grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the stock option agreement by and between the Company and the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options shall be fully vested and exercisable as of December 28, 2021, the date of the grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the stock option agreement by and between the Company and the reporting person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Innocoll Holdings plc
Report date July 24, 2017 · Filed July 26, 2017
Section 16 reporting ended · disclosed 2017-07-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.01 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-07-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-07-24 · Disposition to issuer · Disposed 682,396 · Balance 0 F1: Immediately prior to the Effective Time (as defined below), the Reporting Person beneficially owned (i) 542,396 ordinary shares of the Issuer, par value $0.01 per share ("Ordinary Shares") , and (ii) 140,000 restricted stock units ("RSUs") issued under the Issuer's 2016 Omnibus Incentive Compensation Plan (the "Plan"). F2: Pursuant to the terms of the Transaction Agreement by and among the Issuer, Gurnet Point L.P., a Delaware limited partnership acting through its general partner Waypoint International GP LLC ("Gurnet Point"), and Lough Ree Technologies Limited, an Irish private limited company and wholly-owned subsidiary of Gurnet Point (the "Transaction Agreement"), each Ordinary Share that was beneficially owned by the Reporting Person immediately prior to the effective time of the scheme (the "Effective Time") now represents the right to receive (i) $1.75 in cash and (ii) a contingent value right which represents a contractual right to receive payments up to a maximum aggregate amount of $4.90 in cash upon, and subject to, the occurrence of certain events, without interest and net of applicable tax withholdings (the "Consideration"). F3: Pursuant to the terms of the Transaction Agreement, each RSU that was beneficially owned by the Reporting Person immediately prior to the Effective Time, was cancelled and now represents the right to receive the Consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.80 · Expires 2026-03-30 | Direct | 0 |
Reported balance
After 2017-07-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-07-24 · Disposition to issuer · Disposed 132,500 · Balance 0 F4: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 132,500 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately prior to the Effective Time (as defined below), the Reporting Person beneficially owned (i) 542,396 ordinary shares of the Issuer, par value $0.01 per share ("Ordinary Shares") , and (ii) 140,000 restricted stock units ("RSUs") issued under the Issuer's 2016 Omnibus Incentive Compensation Plan (the "Plan").
F2: Pursuant to the terms of the Transaction Agreement by and among the Issuer, Gurnet Point L.P., a Delaware limited partnership acting through its general partner Waypoint International GP LLC ("Gurnet Point"), and Lough Ree Technologies Limited, an Irish private limited company and wholly-owned subsidiary of Gurnet Point (the "Transaction Agreement"), each Ordinary Share that was beneficially owned by the Reporting Person immediately prior to the effective time of the scheme (the "Effective Time") now represents the right to receive (i) $1.75 in cash and (ii) a contingent value right which represents a contractual right to receive payments up to a maximum aggregate amount of $4.90 in cash upon, and subject to, the occurrence of certain events, without interest and net of applicable tax withholdings (the "Consideration").
F3: Pursuant to the terms of the Transaction Agreement, each RSU that was beneficially owned by the Reporting Person immediately prior to the Effective Time, was cancelled and now represents the right to receive the Consideration.
F4: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 132,500 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2026 Filed Apr 3, 2026 20:38 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 140,498 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023689 · wk-form4_1775248724.xml · derivative · entry 4 Zook Anthony P. · CIK 0001582393 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,998 Underlying: Common Stock · 140,498 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 1, 2025, Mr. Zook was granted 421,496 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:38 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 45,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023689 · wk-form4_1775248724.xml · nonDerivative · entry 2 Zook Anthony P. · CIK 0001582393 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,111 Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:38 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 140,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023689 · wk-form4_1775248724.xml · nonDerivative · entry 1 Zook Anthony P. · CIK 0001582393 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:15 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 406,918 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014146 · wk-form4_1772579744.xml · derivative · entry 4 Zook Anthony P. · CIK 0001582393 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 406,918 Underlying: Common Stock · 406,918 shares Expires not disclosed F3 · derivative.exercise_date: On March 1, 2026, Mr. Zook was granted 406,918 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:15 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 675,676 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001628280-26-014146 · wk-form4_1772579744.xml · derivative · entry 3 Zook Anthony P. · CIK 0001582393 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 675,676 Underlying: Common Stock · 675,676 shares Expires 2036-03-01 F1 · derivative.exercise_price: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 and multiplied by 110%. F2 · derivative.exercise_date: On March 1, 2026, Mr. Zook was granted 675,676 stock options. The options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 21:00 UTC | ADAPTIN BIO, INC. NONE · Entity 9083 | GrantStock Option (right to buy) · Derivative | 109,847 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0001213900-25-086588 · marketforms-70725.xml · derivative · entry 1 Zook Anthony P. · CIK 0001582393 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,847 Underlying: Common Stock · 109,847 shares Expires 2035-09-07 F1 · derivative.exercise_date: The stock option vests in equal monthly installments on the last day of each calendar month over 48 months beginning on September 8, 2025. Read SEC document |
| August 06, 2025 Filed Aug 6, 2025 20:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | PurchaseCommon Stock | 17,900 | $5.58 | $99,953.60 |
DisclosureSEC source: 0001628280-25-038322 · wk-form4_1754510840.xml · nonDerivative · entry 1 Zook Anthony P. · CIK 0001582393 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,066 Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:06 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 12,254 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000123 · wk-form4_1748981195.xml · derivative · entry 4 Zook Anthony P. · CIK 0001582393 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,254 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:06 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 3,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000123 · wk-form4_1748981195.xml · nonDerivative · entry 2 Zook Anthony P. · CIK 0001582393 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,166 F2 · shares: Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the December 1, 2024 vesting of restricted stock. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:06 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 12,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000123 · wk-form4_1748981195.xml · nonDerivative · entry 1 Zook Anthony P. · CIK 0001582393 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 06, 2025 Filed May 8, 2025 20:13 UTC | NEOGENOMICS INC NEO · Entity 2096 | PurchaseCommon Stock | 18,900 | $7.88 | $148,918.77 |
DisclosureSEC source: 0001077183-25-000096 · wk-form4_1746735191.xml · nonDerivative · entry 2 Zook Anthony P. · CIK 0001582393 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Amended and Restated Anthony P. Zook Living Trust Disclosed balance after: 18,900 Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:06 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 421,496 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000058 · wk-form4_1743710801.xml · derivative · entry 3 Zook Anthony P. · CIK 0001582393 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 421,496 Underlying: Common Stock · 421,496 shares Expires not disclosed F3 · derivative.exercise_date: On April 1, 2025, Mr. Zook was granted 421,496 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:06 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 729,927 | $0.00 Strike: $10.44 | $0.00 |
DisclosureSEC source: 0001077183-25-000058 · wk-form4_1743710801.xml · derivative · entry 2 Zook Anthony P. · CIK 0001582393 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 729,927 Underlying: Common Stock · 729,927 shares Expires 2035-04-01 F1 · derivative.exercise_price: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%. F2 · derivative.exercise_date: On April 1, 2025, Mr. Zook was granted 729,927 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| August 10, 2024 Filed Aug 13, 2024 20:40 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 11,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000137 · wk-form4_1723581604.xml · derivative · entry 2 Zook Anthony P. · CIK 0001582393 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,336 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| August 10, 2024 Filed Aug 13, 2024 20:40 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 11,336 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000137 · wk-form4_1723581604.xml · nonDerivative · entry 1 Zook Anthony P. · CIK 0001582393 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:11 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 12,254 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000097 · wk-form4_1717531862.xml · derivative · entry 4 Zook Anthony P. · CIK 0001582393 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,254 Underlying: Common Stock · 12,254 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:11 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 8,672 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001077183-24-000097 · wk-form4_1717531862.xml · derivative · entry 3 Zook Anthony P. · CIK 0001582393 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,672 Underlying: Common Stock · 8,672 shares Expires 2034-06-01 Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:42 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 11,336 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000122 · wk-form4_1692049312.xml · derivative · entry 2 Zook Anthony P. · CIK 0001582393 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,336 Underlying: Common Stock · 11,336 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 21:42 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 8,353 | $0.00 Strike: $14.82 | $0.00 |
DisclosureSEC source: 0001077183-23-000122 · wk-form4_1692049312.xml · derivative · entry 1 Zook Anthony P. · CIK 0001582393 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,353 Underlying: Common Stock · 8,353 shares Expires 2033-08-10 Read SEC document |
| December 28, 2021 Filed Apr 25, 2022 21:22 UTC | Streamex Corp. BSGM · Entity 1816 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001185185-22-000499 · ownership.xml · derivative · entry 1 Zook Anthony P. · CIK 0001582393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-12-28 F1 · derivative.exercise_date: The stock options shall be fully vested and exercisable as of December 28, 2021, the date of the grant, subject to the terms and conditions of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the stock option agreement by and between the Company and the reporting person. Read SEC document |
| July 08, 2020 Filed Jul 11, 2020 01:43 UTC | Streamex Corp. BSGM · Entity 1816 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-20-000988 · ownership.xml · nonDerivative · entry 1 Zook Anthony P. · CIK 0001582393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 23:04 UTC | Innocoll Holdings plc INNL · Entity 12261 | Disposition to issuerStock Option (right to buy) · Derivative | 132,500 | Not disclosed Strike: $8.80 | Not disclosed |
DisclosureSEC source: 0001144204-17-038446 · v471497_4.xml · derivative · entry 2 Zook Anthony P. · CIK 0001582393 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares, par value $0.01 per share · 132,500 shares Expires 2026-03-30 F4 · shares: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 132,500 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F4 · price: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 132,500 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F4 · derivative.exercise_date: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 132,500 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. F4 · derivative.underlying_shares: Immediately prior to the Effective Time, the Reporting Person beneficially owned unexercised options to purchase 132,500 Ordinary Shares (the "Options"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the Options were cancelled without any consideration being payable in respect thereof. Read SEC document |
| July 24, 2017 Filed Jul 26, 2017 23:04 UTC | Innocoll Holdings plc INNL · Entity 12261 | Disposition to issuerOrdinary Shares, par value $0.01 per share | 682,396 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-17-038446 · v471497_4.xml · nonDerivative · entry 1 Zook Anthony P. · CIK 0001582393 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Immediately prior to the Effective Time (as defined below), the Reporting Person beneficially owned (i) 542,396 ordinary shares of the Issuer, par value $0.01 per share ("Ordinary Shares") , and (ii) 140,000 restricted stock units ("RSUs") issued under the Issuer's 2016 Omnibus Incentive Compensation Plan (the "Plan"). F2 · price: Pursuant to the terms of the Transaction Agreement by and among the Issuer, Gurnet Point L.P., a Delaware limited partnership acting through its general partner Waypoint International GP LLC ("Gurnet Point"), and Lough Ree Technologies Limited, an Irish private limited company and wholly-owned subsidiary of Gurnet Point (the "Transaction Agreement"), each Ordinary Share that was beneficially owned by the Reporting Person immediately prior to the effective time of the scheme (the "Effective Time") now represents the right to receive (i) $1.75 in cash and (ii) a contingent value right which represents a contractual right to receive payments up to a maximum aggregate amount of $4.90 in cash upon, and subject to, the occurrence of certain events, without interest and net of applicable tax withholdings (the "Consideration"). F3 · price: Pursuant to the terms of the Transaction Agreement, each RSU that was beneficially owned by the Reporting Person immediately prior to the Effective Time, was cancelled and now represents the right to receive the Consideration. F2 · balance_after: Pursuant to the terms of the Transaction Agreement by and among the Issuer, Gurnet Point L.P., a Delaware limited partnership acting through its general partner Waypoint International GP LLC ("Gurnet Point"), and Lough Ree Technologies Limited, an Irish private limited company and wholly-owned subsidiary of Gurnet Point (the "Transaction Agreement"), each Ordinary Share that was beneficially owned by the Reporting Person immediately prior to the effective time of the scheme (the "Effective Time") now represents the right to receive (i) $1.75 in cash and (ii) a contingent value right which represents a contractual right to receive payments up to a maximum aggregate amount of $4.90 in cash upon, and subject to, the occurrence of certain events, without interest and net of applicable tax withholdings (the "Consideration"). F3 · balance_after: Pursuant to the terms of the Transaction Agreement, each RSU that was beneficially owned by the Reporting Person immediately prior to the Effective Time, was cancelled and now represents the right to receive the Consideration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.